A Nasdaq-listed clinical-stage biopharma firm advancing novel therapies for oncology and neurodegenerative disorders with a strong balance sheet despite recent operational losses.
Investors may view Zentalis as an attractive turnaround play given the significant year-over-year improvement in net income from -$292.3M to -$165.9M. The company's substantial accumulated other comprehensive income and strong cash on hand suggest a solid foundation for funding future clinical milestones without immediate equity dilution.
The persistent negative operating profit of -$191.2M and a retained earnings deficit of -$1.05B indicate ongoing financial distress that could limit growth potential. With general and administrative expenses reaching $87.1M against only $67.4M in revenue, the company burns cash at a rate that threatens long-term viability if new partnerships do not materialize quickly.
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in oncology, immuno-oncology, and neurodegenerative diseases. Headquartered in the United States, the firm focuses on developing innovative therapies for patients with rare cancers and neurological conditions through its proprietary platform technologies.
Despite a substantial net loss of $165.9M in 2024, Zentalis demonstrated operational resilience by reducing losses from $292.3M in 2023 and $237.1M in 2022. The company generated positive cash flow from investing activities of $176.6M, likely driven by strategic partnerships or asset sales, while maintaining a healthy net change in cash of $5.8M.
The biopharmaceutical industry is characterized by high barriers to entry, significant R&D costs, and reliance on successful clinical trial outcomes for value creation. Companies like Zentalis operate in a capital-intensive environment where value is often created through strategic licensing rather than traditional product sales until late-stage approval.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $67.4M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $67.4M |
| Operating Expenses | $227.3M | $299.5M | $258.6M |
| Operating Income | $-227.3M | $-299.5M | $-191.2M |
| R&D | $172.7M | $189.6M | $167.8M |
| G&A | $54.6M | $64.4M | $87.1M |
| Stock-Based Comp | $46.8M | $54.8M | $67.3M |
| D&A | $1.4M | $1.4M | $1.3M |
| Other OpEx | $0 | $45.6M | $3.7M |
| Non-Operating Income | $-10.3M | $6.6M | $25.5M |
| Pre-Tax Income | $-237.6M | $-292.9M | $-165.7M |
| Income Tax | $-469.0K | $-601.0K | $177.0K |
| Continuing Ops | $-237.1M | $-292.3M | $-165.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-237.1M | $-292.3M | $-165.9M |
| Minority Interest | $-307.0K | $-114.0K | $-28.0K |
| Net to Common | $-236.8M | $-292.2M | $-165.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $451.9M | $496.7M | $386.1M |
| Cash & Equivalents | $43.1M | $28.0M | $33.9M |
| Accounts Receivable | — | — | $5.0M |
| Prepaid Expenses | $14.6M | $13.8M | $10.0M |
| Other Current Assets | $394.3M | $454.9M | $337.2M |
| Long-Term Assets | $87.4M | $55.0M | $44.3M |
| PP&E (Net) | $7.7M | $5.8M | $4.7M |
| Goodwill | $3.7M | $3.7M | $0 |
| Operating Leases | $42.4M | $35.9M | $32.5M |
| Other LT Assets | $12.3M | $9.5M | $7.0M |
| Total Assets | $539.3M | $551.7M | $430.3M |
| Current Liabilities | $56.6M | $69.4M | $52.7M |
| Accounts Payable | $11.2M | $14.9M | $7.4M |
| Current Leases | $2.2M | $2.6M | $3.1M |
| Taxes Payable | $384.0K | $281.0K | $0 |
| Other Current Liab | $-2.5M | $-2.9M | $-3.1M |
| Long-Term Liabilities | $48.6M | $44.9M | $40.4M |
| LT Operating Leases | $45.2M | $43.1M | $39.6M |
| Other LT Liab | $3.5M | $1.8M | $849.0K |
| Total Liabilities | $105.3M | $114.3M | $93.2M |
| Shareholders' Equity | $434.0M | $437.4M | $337.2M |
| Paid-In Capital | $1.03B | $1.32B | $1.39B |
| Retained Earnings | $-596.4M | $-888.6M | $-1.05B |
| AOCI | $-1.4M | $2.2M | $558.0K |
| Total L&E | $539.3M | $551.7M | $430.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-237.1M | $-292.3M | $-165.9M |
| Non-Cash Adjustments | $50.5M | $67.9M | $14.2M |
| Working Capital Changes | $22.9M | $16.6M | $-19.2M |
| Cash from Operations | $-163.8M | $-207.8M | $-170.9M |
| Capital Expenditures | $2.5M | $583.0K | $221.0K |
| Cash from Investing | $-114.2M | $-44.5M | $176.6M |
| Cash from Financing | $261.0M | $237.3M | $108.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-16.9M | $-15.0M | $5.8M |
| Beginning Cash | $62.6M | $45.7M | $30.7M |
| Ending Cash | $45.7M | $30.7M | $36.5M |
The company's financial profile indicates a focus on R&D-driven development across oncology, immuno-oncology, and rare disease indications. Revenue of $67.4M is primarily derived from collaborations and licensing agreements typical of clinical-stage biotech firms rather than commercial product sales, supported by significant investments in research and development totaling $167.8M.
The company faces high risk of clinical trial failures which could abruptly halt development pipelines and deplete cash reserves. Significant operating losses of $165.9M highlight the capital intensity required to advance candidates through late-stage trials before potential commercialization. Dependence on external funding sources remains critical given the negative net income trend over the last three years.
Zentalis leverages proprietary intellectual property platforms designed to overcome biological barriers in hard-to-treat diseases like ovarian cancer and amyotrophic lateral sclerosis. The company maintains a robust cash position with $33.9M in cash and equivalents, providing flexibility for strategic asset acquisition or licensing deals without immediate need for dilutive financing.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.